Government-Owned Inventions; Availability for Licensing, 21638-21640 [2010-9641]
Download as PDF
<![CDATA[
21638
Federal Register / Vol. 75, No. 79 / Monday, April 26, 2010 / Notices
sroberts on DSKD5P82C1PROD with NOTICES
Krensky AM, Modlin RL. An
antimicrobial activity of cytolytic T cells
mediated by granulysin. Science 1998
Oct 2;282(5386):121–125. [PubMed:
9756476]
2. Krensky AM and Clayberger C.
Biology and clinical relevance of
granulysin. Tissue Antigens 2009
Mar;73(3):193–198. [PubMed: 19254247]
Patent Status: U.S. Provisional
Application No. 61/250,601 filed 12 Oct
2009 (HHS Reference No. E–158–2009/
0–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: Whitney Hastings,
M.S.; 301–451–7337;
hastingw@mail.nih.gov.
Collaborative Research Opportunity:
The Center for Cancer Research,
Laboratory of Cellular and Molecular
Biology, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this technology. Please
contact John Hewes, Ph.D. at 301–435–
3131 or hewesj@mail.nih.gov for more
information.
Fully-Human Monoclonal Antibodies
Against Human EphrinB2 and EphB4
for Use in the Study of Cancer
Pathogenesis
Description of Invention: Ephrin
receptor tyrosine kinases and their
ephrin ligands have been implicated in
cancer pathogenesis. Ephrin receptors
and ligands affect tumor growth,
invasiveness, angiogenesis, and
metastasis. Ephrin signaling activities in
cancer are complex and are only now
beginning to be uncovered.
Researchers at the National Cancer
Institute-Frederick, NIH, have
developed a set of five fully-human
monoclonal antibodies against human
Ephrin-B2 and Ephrin type-B receptor 4
(‘‘EphB4’’). The antibodies were
¨
identified by screening a naıve human
antibody phage display library against
Ephrin-B2 and EphB4. These human
monoclonal antibodies have high
affinity and specificity for Ephrin-B2
and EphB4.
Applications:
• Research reagents for in vitro/in
vivo investigation of Ephrin receptor
and ligand interactions.
• Targeting reagents for in vivo
imaging.
• Research reagents for protein cocrystallization.
Advantages:
• High affinity and antigen
specificity.
• Bind both soluble ectodomains and
cell surface-expressed molecules.
Inventors: Dimiter S. Dimitrov et al.
(NCI).
VerDate Nov<24>2008
16:56 Apr 23, 2010
Jkt 220001
Patent Status: HHS Reference No. E–
331–2008/0 & E–331–2008/1—Research
Material. Patent protection is not being
pursued for this technology.
Licensing Status: Available for
licensing.
Licensing Contact: Patrick P. McCue,
Ph.D.; 301–435–5560;
mccuepat@mail.nih.gov.
Collaborative Research Opportunity:
The Center for Cancer Research
Nanobiology Program is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize this technology. Please
contact John Hewes, Ph.D. at 301–435–
3131 or hewesj@mail.nih.gov for more
information.
Dated: April 20, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2010–9642 Filed 4–23–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION:
Notice.
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
ADDRESSES:
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
New Mouse Strain With Conditional
Deletion of SMAD7: Analysis of Disease
Processes Involving Immunological,
Fibrotic or Cardiovascular Indications
Description of Invention: SMAD7
conditional knockout mice are available
for licensing. SMAD7 can be knocked
out by breeding with CRE-recombinase
transgenic mice with a variety of
promoters to yield tissue or cell typespecific deletions of SMAD7. SMAD7
has been shown to play a role in bone
morphogenesis, cardiovascular tissue
generation, immune regulation and
fibrosis. Therefore, these mice provide a
unique model to examine the role of the
SMAD7 gene in disease processes that
involve immunological, fibrotic, or
cardiovascular components.
Specifically, these mice may represent a
novel model of Scleroderma, a disease
with both an immunological and fibrotic
component.
Applications:
• Mouse model of Scleroderma.
• Means of studying bone
morphogenesis and cardiovascular
tissue generation.
• Means of studying the role of
SMAD7 in immune regulation.
Inventors: Marilyn Diaz (NIEHS).
Related Publication: Dong C, Zhu S,
Wang T, Yoon W, Li Z, Alvarez RJ, Dijke
P, White B, Wigley FM, GodschmidtClermont PJ. Deficient Smad7
expression: A putative molecular defect
in scleroderma. Proc Natl Acad Sci
USA. 2002 Mar 19;99(6):3908–3913.
[PubMed: 11904440]
Patent Status: HHS Reference No. E–
040–2010/0—Research Material. Patent
protection is not being pursued for this
technology.
Licensing Status: This technology is
available as a research tool under a
Biological Materials License.
Licensing Contact: Steve Standley,
Ph.D.; 301–435–4074;
sstand@od.nih.gov.
Collaborative Research Opportunity:
The NIEHS is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this technology. Please
contact Dr. Elizabeth M. Denholm,
denholme@niehs.nih.gov, for more
information.
A Method of Reducing Cholesterol
Biosynthesis With Specific MicroRNAs
Description of Invention: This
technology is directed to the discovery
of specific microRNAs that target and
downregulate enzymes within the
cholesterol biosynthetic pathway and is
currently being tested in vivo.
Briefly, microRNAs regulate the
translation of messenger RNAs (mRNAs)
E:\FR\FM\26APN1.SGM
26APN1
sroberts on DSKD5P82C1PROD with NOTICES
Federal Register / Vol. 75, No. 79 / Monday, April 26, 2010 / Notices
into protein. The inventors have
discovered a set of specific microRNAs
that downregulate the expression of
multiple enzymes in the cholesterol
biosynthetic pathway. Importantly, this
technology may provide the benefits of
cholesterol lowering therapies to
patients that are not suited for statinbased treatments. Statins block the
cholesterol biosynthetic pathway at a
single enzymatic step and may result in
the deleterious build-up of a metabolic
intermediate. In contrast, this
technology simultaneously targets the
expression of multiple enzymes
required for cholesterol biosynthesis
and thus may avoid the build-up of
metabolic intermediates. The reduction
of cholesterol biosynthesis has been
indicated for improved cardiovascular
health and lowers the risk for heart
disease, heart attack, and stroke.
Potential Applications and
Advantages:
• A method of reducing cellular
cholesterol biosynthesis.
• A method of reducing systemic
cholesterol in a subject.
• May be effective for patients not
suited for statin-based treatment.
• Targets multiple enzymes in the
cholesterol biosynthetic pathway
simultaneously.
Development Status: Early stage.
Market: According to the Centers for
Disease Control (CDC), approximately
one in every six adults has high
cholesterol and individuals with high
total cholesterol have approximately
twice the risk of heart disease in
comparison to individuals with optimal
levels.
Inventors: Kasey Vickers and Alan
Remaley (NHLBI).
Publication: Vickers KC and Remaley
AT. MicroRNAs in atherosclerosis and
lipoprotein metabolism. Curr Opin
Endocrinol Diabetes Obesity. 2010
Apr;17(2):150–155; DOI 10.1097/
MED.0b013e32833727a1. [PubMed:
20150807]
Patent Status: U.S. Provisional
Application No. 61/280,170 filed 30 Oct
2009 (HHS Reference No. E–142–2009/
0–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: Fatima Sayyid,
MHPM; 301–435–4521;
Fatima.Sayyid@nih.hhs.gov.
Collaborative Research Opportunity:
The National Heart, Lung and Blood
Institute, Pulmonary Vascular Medicine
Branch, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize microRNA regulation of
the cholesterol biosynthetic pathway.
VerDate Nov<24>2008
16:56 Apr 23, 2010
Jkt 220001
Please contact Dr. Denise M. Crooks at
301–435–0103, crooksd@nhlbi.nih.gov
for more information.
Moraxella Catarrhalis
Lipooligosaccharide Based Conjugate
Vaccines for the Prevention of Otitis
Media and Respiratory Infections
Description of Invention: Moraxella
catarrhalis is one of the three leading
causative agents of otitis media in
children. This is due in part to the
current immunizations of children with
Streptococcus pneumoniae
polysaccharide and conjugate vaccines
to prevent otitis media. The proportion
of otitis media caused by pneumococcal
strains covered by the vaccines have
decreased while those caused by
Moraxella catarrhalis and nontypeable
Haemophilus influenzae have
significantly increased. At some point
during early childhood, otitis media
affects more than 80% of children under
6 years of age. Otitis media can lead to
deafness and language or learning
deficits. In adults, Moraxella catarrhalis
is a major cause of bronchopneumonia
and exacerbation of existing chronic
obstructive pulmonary disease for
chronic heavy smokers or elderly
patients with chronic pulmonary
disease. Moraxella catarrhalis infections
can be treated with antimicrobial agents;
however, the emergence of antibiotic
resistance makes vaccines against
Moraxella catarrhalis an attractive
alternative to antimicrobial drugs. There
are currently no Moraxella catarrhalis
vaccines on the market.
The subject technologies are conjugate
vaccines against Moraxella catarrhalis.
The vaccines are comprised of isolated
lipooligosaccharides (LOS) from which
esterified fatty acids have been removed
to produce detoxified LOS or from
which lipid A has been removed to
produce a detoxified oligosaccharide
(OS) covalently linked to an
immunogenic carrier such as tetanus
toxoid, and adjuvants such as alum. The
vaccines can potentially be used as a
vaccine component in a combination
vaccine containing other pediatric
vaccine components.
Applications: Vaccines for the
prevention of respiratory infections and
otitis media caused by Moraxella
catarrhalis.
Advantages:
• Novel vaccine candidates.
• LOS is a conserved antigen.
Development Status: In vitro and in
vivo (mouse animal model) data is
available and can be provided upon
request.
Market:
• Pediatric vaccines.
• Preventative vaccines.
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
21639
Inventors: Xin-Xing Gu (NIDCD) and
John Robbins (NICHD).
Related Publications: Manuscripts in
preparation, available upon request
under a confidential disclosure
agreement.
Patent Status:
• U.S. Patent 6,685,949 issued 03 Feb
2004 (HHS Ref. No. E–264–1997/0–US–
13).
• U.S. Patent 7,641,906 issued 05 Jan
2010 (HHS Ref. No. E–217–2001/0–US–
06).
Licensing Status: Available for
licensing.
Licensing Contact: Kevin W. Chang,
Ph.D.; 301–435–5018;
changke@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute on Deafness and
Other Communication Disorders,
Vaccine Research Section, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize the subject technology.
Please contact Brian W. Bailey, Ph.D. at
301–594–4094 or bbailey@mail.nih.gov
for more information.
Nontypeable Haemophilus
Influenzae Lipooligosaccharide Based
Conjugate Vaccines for the Prevention
of Otitis Media and Respiratory
Infections
Description of Invention: Nontypeable
Haemophilus influenzae is one of the
leading causative agents of otitis media
in children and accounts for 11% of
pneumonia cases in children. This is
due in part to the current
immunizations of children with
Streptococcus pneumoniae
polysaccharide and conjugate vaccines
to prevent otitis media. The proportion
of otitis media caused by pneumococcal
strains covered by the vaccines have
decreased while those caused by
nontypeable Haemophilus influenzae
have significantly increased. At some
point during early childhood, otitis
media affects more than 80% of
children under 6 years of age. Otitis
media can lead to deafness and language
or learning deficits. In adults,
nontypeable Haemophilus influenzae
causes respiratory tract infections
primarily in persons with chronic
obstructive pulmonary disease, one of
the most common lung diseases.
Exacerbation of chronic obstructive
pulmonary disease in the elderly is the
fourth leading cause of death in the
United States. Otitis media can be
treated with antibiotics; however, the
emergence of antibiotic resistance
makes vaccines against nontypeable
Haemophilus influenzae an attractive
alternative to those classes of drugs. The
E:\FR\FM\26APN1.SGM
26APN1
sroberts on DSKD5P82C1PROD with NOTICES
21640
Federal Register / Vol. 75, No. 79 / Monday, April 26, 2010 / Notices
current Haemophilus influenzae type b
conjugate vaccines have no protective
effect against nontypeable strains.
The technologies described herein are
conjugate vaccines against nontypeable
Haemophilus influenzae. The vaccines
are comprised of lipooligosaccharides
(LOS) from which esterified fatty acids
have been removed from lipid A to form
detoxified LOS conjugated to an
immunogenic carrier such as tetanus
toxoid, and an adjuvant such as alum.
In vivo data in the Chinchilla animal
model are available. The vaccines can
be potentially used as a component in
a combination vaccine with other
pediatric vaccine components.
Applications: Vaccines for the
prevention of respiratory infections and
otitis media caused by nontypeable
Haemophilus influenzae.
Advantages:
• Novel vaccine candidates.
• Conserved antigen.
Development Status: In vitro and in
vivo data can be provided upon request.
Data is also available from a phase I
clinical trial with a representative
vaccine showing safety and
immunogenicity in adults.
Market:
• Pediatric vaccines.
• Preventative vaccines.
Inventors: Xin-xing Gu (NIDCD), John
Robbins (NICHD), et al.
Related Publication: W Hong et al.
Protection against nontypeable
Haemophilus influenzae challenges by
mucosal vaccination with a detoxified
lipooligosaccharide conjugate in two
chinchilla models. Microbes Infect.
2010 Jan;12(1):11–18. [PubMed:
19782149]
Patent Status:
• U.S. Patent 6,207,157 issued 27 Mar
2001 (HHS Ref. No. E–228–1995/1–US–
01).
• U.S. Patent 6,607,725 issued 19 Aug
2003 (HHS Ref. No. E–228–1995/1–US–
02).
• U.S. Patent 7,641,906 issued 05 Jan
2010 (HHS Ref. No. E–217–2001/0–US–
06).
Licensing Status: Available for
licensing.
Licensing Contact: Kevin W. Chang,
Ph.D.; 301–435–5018;
changke@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute on Deafness and
Other Communication Disorders,
Vaccine Research Section, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize the subject technology.
Please contact Brian W. Bailey, Ph.D. at
301–594–4094 or bbailey@mail.nih.gov
for more information.
VerDate Nov<24>2008
16:56 Apr 23, 2010
Jkt 220001
Dated: April 20, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2010–9641 Filed 4–23–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel, T32
Review.
Date: May 11, 2010.
Time: 5 p.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Crystal City, 2399 Jefferson
Davis Hwy, Arlington, VA 22202.
Contact Person: Robert Bird, PhD, Chief,
Resources and Training Review Branch,
Division of Extramural Activities, National
Cancer Institute, 6116 Executive Boulevard,
Room 8113, Bethesda, MD 20892–8328, 301–
496–7978, birdr@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel,
Epidemiology, Prevention, Control and
Population Sciences.
Date: May 26–27, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Washington DC/Rockville,
Rockville, MD 20852.
Contact Person: Wlodek Lopaczynski,
M.D., PhD, Scientific Review Officer,
Research Programs Review Branch, Division
of Extramural Activities, National Cancer
Institute, 6116 Executive Blvd., Room 8131,
Bethesda, MD 20892, 301–594–1402,
lopacw@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, Cellular &
Tissue Biology P01.
Date: May 26–28, 2010.
Time: 5 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Shakeel Ahmad, PhD,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
6116 Executive Boulevard, Room 8139,
Bethesda, MD 20892–8328, (301) 594–0114,
ahmads@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, State and
Community Tobacco Control Policy and
Media Research.
Date: May 26–27, 2010.
Time: 7 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Legacy Hotel and Conference Center,
1775 Rockville Pike, Rockville, MD 20852.
Contact Person: Gerald G. Lovinger, PhD,
Scientific Review Officer, Special Review
and Logistics Branch, Division of Extramural
Activities, National Cancer Institute, 6116
Executive Blvd., Room 8101, Bethesda, MD
20892–8329, 301/496–7987,
lovingeg@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: April 20, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–9636 Filed 4–23–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
application, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
E:\FR\FM\26APN1.SGM
26APN1
]]>Agencies
[Federal Register Volume 75, Number 79 (Monday, April 26, 2010)]
[Notices]
[Pages 21638-21640]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-9641]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
New Mouse Strain With Conditional Deletion of SMAD7: Analysis of
Disease Processes Involving Immunological, Fibrotic or Cardiovascular
Indications
Description of Invention: SMAD7 conditional knockout mice are
available for licensing. SMAD7 can be knocked out by breeding with CRE-
recombinase transgenic mice with a variety of promoters to yield tissue
or cell type-specific deletions of SMAD7. SMAD7 has been shown to play
a role in bone morphogenesis, cardiovascular tissue generation, immune
regulation and fibrosis. Therefore, these mice provide a unique model
to examine the role of the SMAD7 gene in disease processes that involve
immunological, fibrotic, or cardiovascular components. Specifically,
these mice may represent a novel model of Scleroderma, a disease with
both an immunological and fibrotic component.
Applications:
Mouse model of Scleroderma.
Means of studying bone morphogenesis and cardiovascular
tissue generation.
Means of studying the role of SMAD7 in immune regulation.
Inventors: Marilyn Diaz (NIEHS).
Related Publication: Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarez
RJ, Dijke P, White B, Wigley FM, Godschmidt-Clermont PJ. Deficient
Smad7 expression: A putative molecular defect in scleroderma. Proc Natl
Acad Sci USA. 2002 Mar 19;99(6):3908-3913. [PubMed: 11904440]
Patent Status: HHS Reference No. E-040-2010/0--Research Material.
Patent protection is not being pursued for this technology.
Licensing Status: This technology is available as a research tool
under a Biological Materials License.
Licensing Contact: Steve Standley, Ph.D.; 301-435-4074;
sstand@od.nih.gov.
Collaborative Research Opportunity: The NIEHS is seeking statements
of capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize this
technology. Please contact Dr. Elizabeth M. Denholm,
denholme@niehs.nih.gov, for more information.
A Method of Reducing Cholesterol Biosynthesis With Specific MicroRNAs
Description of Invention: This technology is directed to the
discovery of specific microRNAs that target and downregulate enzymes
within the cholesterol biosynthetic pathway and is currently being
tested in vivo.
Briefly, microRNAs regulate the translation of messenger RNAs
(mRNAs)
[[Page 21639]]
into protein. The inventors have discovered a set of specific microRNAs
that downregulate the expression of multiple enzymes in the cholesterol
biosynthetic pathway. Importantly, this technology may provide the
benefits of cholesterol lowering therapies to patients that are not
suited for statin-based treatments. Statins block the cholesterol
biosynthetic pathway at a single enzymatic step and may result in the
deleterious build-up of a metabolic intermediate. In contrast, this
technology simultaneously targets the expression of multiple enzymes
required for cholesterol biosynthesis and thus may avoid the build-up
of metabolic intermediates. The reduction of cholesterol biosynthesis
has been indicated for improved cardiovascular health and lowers the
risk for heart disease, heart attack, and stroke.
Potential Applications and Advantages:
A method of reducing cellular cholesterol biosynthesis.
A method of reducing systemic cholesterol in a subject.
May be effective for patients not suited for statin-based
treatment.
Targets multiple enzymes in the cholesterol biosynthetic
pathway simultaneously.
Development Status: Early stage.
Market: According to the Centers for Disease Control (CDC),
approximately one in every six adults has high cholesterol and
individuals with high total cholesterol have approximately twice the
risk of heart disease in comparison to individuals with optimal levels.
Inventors: Kasey Vickers and Alan Remaley (NHLBI).
Publication: Vickers KC and Remaley AT. MicroRNAs in
atherosclerosis and lipoprotein metabolism. Curr Opin Endocrinol
Diabetes Obesity. 2010 Apr;17(2):150-155; DOI 10.1097/
MED.0b013e32833727a1. [PubMed: 20150807]
Patent Status: U.S. Provisional Application No. 61/280,170 filed 30
Oct 2009 (HHS Reference No. E-142-2009/0-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Fatima Sayyid, MHPM; 301-435-4521;
Fatima.Sayyid@nih.hhs.gov.
Collaborative Research Opportunity: The National Heart, Lung and
Blood Institute, Pulmonary Vascular Medicine Branch, is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
microRNA regulation of the cholesterol biosynthetic pathway. Please
contact Dr. Denise M. Crooks at 301-435-0103, crooksd@nhlbi.nih.gov for
more information.
Moraxella Catarrhalis Lipooligosaccharide Based Conjugate Vaccines for
the Prevention of Otitis Media and Respiratory Infections
Description of Invention: Moraxella catarrhalis is one of the three
leading causative agents of otitis media in children. This is due in
part to the current immunizations of children with Streptococcus
pneumoniae polysaccharide and conjugate vaccines to prevent otitis
media. The proportion of otitis media caused by pneumococcal strains
covered by the vaccines have decreased while those caused by Moraxella
catarrhalis and nontypeable Haemophilus influenzae have significantly
increased. At some point during early childhood, otitis media affects
more than 80% of children under 6 years of age. Otitis media can lead
to deafness and language or learning deficits. In adults, Moraxella
catarrhalis is a major cause of bronchopneumonia and exacerbation of
existing chronic obstructive pulmonary disease for chronic heavy
smokers or elderly patients with chronic pulmonary disease. Moraxella
catarrhalis infections can be treated with antimicrobial agents;
however, the emergence of antibiotic resistance makes vaccines against
Moraxella catarrhalis an attractive alternative to antimicrobial drugs.
There are currently no Moraxella catarrhalis vaccines on the market.
The subject technologies are conjugate vaccines against Moraxella
catarrhalis. The vaccines are comprised of isolated
lipooligosaccharides (LOS) from which esterified fatty acids have been
removed to produce detoxified LOS or from which lipid A has been
removed to produce a detoxified oligosaccharide (OS) covalently linked
to an immunogenic carrier such as tetanus toxoid, and adjuvants such as
alum. The vaccines can potentially be used as a vaccine component in a
combination vaccine containing other pediatric vaccine components.
Applications: Vaccines for the prevention of respiratory infections
and otitis media caused by Moraxella catarrhalis.
Advantages:
Novel vaccine candidates.
LOS is a conserved antigen.
Development Status: In vitro and in vivo (mouse animal model) data
is available and can be provided upon request.
Market:
Pediatric vaccines.
Preventative vaccines.
Inventors: Xin-Xing Gu (NIDCD) and John Robbins (NICHD).
Related Publications: Manuscripts in preparation, available upon
request under a confidential disclosure agreement.
Patent Status:
U.S. Patent 6,685,949 issued 03 Feb 2004 (HHS Ref. No. E-
264-1997/0-US-13).
U.S. Patent 7,641,906 issued 05 Jan 2010 (HHS Ref. No. E-
217-2001/0-US-06).
Licensing Status: Available for licensing.
Licensing Contact: Kevin W. Chang, Ph.D.; 301-435-5018;
changke@mail.nih.gov.
Collaborative Research Opportunity: The National Institute on
Deafness and Other Communication Disorders, Vaccine Research Section,
is seeking statements of capability or interest from parties interested
in collaborative research to further develop, evaluate, or
commercialize the subject technology. Please contact Brian W. Bailey,
Ph.D. at 301-594-4094 or bbailey@mail.nih.gov for more information.
Nontypeable Haemophilus Influenzae Lipooligosaccharide Based Conjugate
Vaccines for the Prevention of Otitis Media and Respiratory Infections
Description of Invention: Nontypeable Haemophilus influenzae is one
of the leading causative agents of otitis media in children and
accounts for 11% of pneumonia cases in children. This is due in part to
the current immunizations of children with Streptococcus pneumoniae
polysaccharide and conjugate vaccines to prevent otitis media. The
proportion of otitis media caused by pneumococcal strains covered by
the vaccines have decreased while those caused by nontypeable
Haemophilus influenzae have significantly increased. At some point
during early childhood, otitis media affects more than 80% of children
under 6 years of age. Otitis media can lead to deafness and language or
learning deficits. In adults, nontypeable Haemophilus influenzae causes
respiratory tract infections primarily in persons with chronic
obstructive pulmonary disease, one of the most common lung diseases.
Exacerbation of chronic obstructive pulmonary disease in the elderly is
the fourth leading cause of death in the United States. Otitis media
can be treated with antibiotics; however, the emergence of antibiotic
resistance makes vaccines against nontypeable Haemophilus influenzae an
attractive alternative to those classes of drugs. The
[[Page 21640]]
current Haemophilus influenzae type b conjugate vaccines have no
protective effect against nontypeable strains.
The technologies described herein are conjugate vaccines against
nontypeable Haemophilus influenzae. The vaccines are comprised of
lipooligosaccharides (LOS) from which esterified fatty acids have been
removed from lipid A to form detoxified LOS conjugated to an
immunogenic carrier such as tetanus toxoid, and an adjuvant such as
alum. In vivo data in the Chinchilla animal model are available. The
vaccines can be potentially used as a component in a combination
vaccine with other pediatric vaccine components.
Applications: Vaccines for the prevention of respiratory infections
and otitis media caused by nontypeable Haemophilus influenzae.
Advantages:
Novel vaccine candidates.
Conserved antigen.
Development Status: In vitro and in vivo data can be provided upon
request. Data is also available from a phase I clinical trial with a
representative vaccine showing safety and immunogenicity in adults.
Market:
Pediatric vaccines.
Preventative vaccines.
Inventors: Xin-xing Gu (NIDCD), John Robbins (NICHD), et al.
Related Publication: W Hong et al. Protection against nontypeable
Haemophilus influenzae challenges by mucosal vaccination with a
detoxified lipooligosaccharide conjugate in two chinchilla models.
Microbes Infect. 2010 Jan;12(1):11-18. [PubMed: 19782149]
Patent Status:
U.S. Patent 6,207,157 issued 27 Mar 2001 (HHS Ref. No. E-
228-1995/1-US-01).
U.S. Patent 6,607,725 issued 19 Aug 2003 (HHS Ref. No. E-
228-1995/1-US-02).
U.S. Patent 7,641,906 issued 05 Jan 2010 (HHS Ref. No. E-
217-2001/0-US-06).
Licensing Status: Available for licensing.
Licensing Contact: Kevin W. Chang, Ph.D.; 301-435-5018;
changke@mail.nih.gov.
Collaborative Research Opportunity: The National Institute on
Deafness and Other Communication Disorders, Vaccine Research Section,
is seeking statements of capability or interest from parties interested
in collaborative research to further develop, evaluate, or
commercialize the subject technology. Please contact Brian W. Bailey,
Ph.D. at 301-594-4094 or bbailey@mail.nih.gov for more information.
Dated: April 20, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-9641 Filed 4-23-10; 8:45 am]
BILLING CODE 4140-01-P
